Since its inception in 1956, the Lymphoid Malignancies Branch (formerly the Metabolism Branch) has been an exemplar of translational research. Its investigators combine basic research, preclinical investigation, and drug development with innovative, therapeutic clinical trials that have as their scientific basis fundamental research performed in the Branch. Primary interests of the Branch concern the identification of abnormalities to the regulation of the immune response and the definition of molecular disorders that underlie lymphoid malignancies. The fundamental laboratory-based studies concern molecular biology of human lymphoid malignancies (Louis Staudt); the Staudt Laboratory uses genomic approaches to establish a molecular diagnosis of lymphoid malignancies and to discover new targets for therapy of these diseases.
A mainstay of the Laboratory is gene-expression profiling, which provides a foundation to understand the molecular pathogenesis of these cancers and their response to therapy. New molecular subtypes of lymphoma defined by gene-expression profiling emerge as distinct disease entities that differ in oncogenic mechanisms, as defined by other genomic technologies such as array-based comparative genomic hybridization and cancer gene resequencing. An ongoing interest is in RNA interference (RNAi)-based genetic screens for new therapeutic targets in lymphoma and multiple myeloma. A recurrent theme that emerges from these unbiased genetic approaches is that lymphoid malignancies co-opt signaling proteins and transcription factors that are used in normal B-cell differentiation and activation. These lymphoid restricted pathways provide opportunities for the development of targeted therapies for lymphoid cancers.
A major specific research goal of the Waldmann Laboratory immunological research program is to define the pivotal roles played by IL-2 and IL-15 (cytokine/cytokine receptors and signaling pathways) in the life and death of normal and neoplastic lymphocytes. Furthermore we clinically translate our basic discoveries of new cytokines (e.g., IL-15) and new cytokine receptors (e.g., IL-2R alpha and IL-2/IL-15R beta) and their signaling pathways through the use of IL-15 in immunotherapy and monoclonal antibodies to receptors (anti-IL-2R alpha and anti-IL-2/IL-15R beta) in the treatment of autoimmune diseases and lymphoid malignancies.
Our group also focuses on T-cell malignancies with special emphasis on human T-cell lymphotropic virus 1 (HTLV-1)-associated adult T-cell leukemia (ATL) (Kevin Conlon, Thomas Waldmann). A major goal of the Branch is to translate fundamental biologic insights into novel treatment of human B and T-cell lymphoid malignancies. The major clinical research emphasis is the development of the most effective therapeutic strategies in molecular subtypes of aggressive B-cell lymphomas. The dose-adjusted EPOCH-R platform has demonstrated excellent long-term results in Burkitt lymphoma as well as subsets of diffuse large B-cell lymphoma (DLBCL) such as primary mediastinal B-cell lymphoma (PMBL) and GCB DLBCL.
Collaboration with Louis Staudt, Wyndham Wilson and colleagues (Mark Roschewski) has led to the clinical development of novel agents that target pathways of ABC DLBCL such as the Bruton's tyrosine kinase inhibitor, ibrutinib. Currently, it is being prospectively tested in a multicenter study of DLBCL with MYC translocations.
-
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0014Investigator Christopher J. Melani, M.D. -
A Phase 1 Study of Doxorubicin, CC-486 (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0169Investigator Milos Miljković, M.D., M.Sc. -
A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies#xD;
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0162Investigator Mark Roschewski, M.D. -
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/refractory T-cell Malignancies
Open - RecruitingNCI Protocol ID NCI-20-C-0127Investigator Milos Miljković, M.D., M.Sc. -
Avelumab (Bavencio) with IL-15 in subjects with clear-cell renal carcinoma
Open - RecruitingNCI Protocol ID NCI-20-C-0007Investigator Kevin C. Conlon, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell Lymphoma
Open - RecruitingNCI Protocol ID NCI-19-C-0116Investigator Mark Roschewski, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)
Open - RecruitingNCI Protocol ID NCI-19-C-0103Investigator Mark Roschewski, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Open - RecruitingNCI Protocol ID NCI-19-C-0076Investigator Milos Miljković, M.D., M.Sc.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Open - RecruitingNCI Protocol ID NCI-19-C-0024Investigator Milos Miljković, M.D., M.Sc.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
Open - RecruitingNCI Protocol ID NCI-17-C-0164Investigator Mark Roschewski, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
Phase 1b Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Open - RecruitingNCI Protocol ID NCI-17-C-0127Investigator Christopher J. Melani, M.D.Share this trial: Referral ContactsContact Name Phone Number -
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Open - RecruitingNCI Protocol ID NCI-17-C-0125Investigator Christopher J. Melani, M.D. -
Prospective Study of Clonal Evolution in Follicular Lymphoma
Open - RecruitingNCI Protocol ID NCI-17-C-0105Investigator Mark Roschewski, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 Sarah Evans 240.858.3541 -
Phase 1 Study of Ibrutinib and Immuno-chemotherapy using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Open - RecruitingNCI Protocol ID NCI-14-C-0157Investigator Mark Roschewski, M.D. -
Phase I/II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Smoldering and Chronic Adult T-cell Leukemia (ATL)
Open - RecruitingNCI Protocol ID NCI-13-C-0006Investigator Kevin C. Conlon, M.D.Share this trial: Referral ContactsContact Name Phone Number Medical Oncology Referral Office 301-451-1228 Medical Oncology Referral Office 866-611-6310 -
Collection of Blood, Bone Marrow and Tissue samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection
Open - RecruitingNCI Protocol ID NCI-97-C-0143Investigator Thomas A. Waldmann, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Open - RecruitingNCI Protocol ID NCI-94-C-0074Investigator Christopher J. Melani, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050
There are no Open Positions at this time. Check back again later, or take a look at CCR's Careers page.
About
Since its inception in 1956, the Lymphoid Malignancies Branch (formerly the Metabolism Branch) has been an exemplar of translational research. Its investigators combine basic research, preclinical investigation, and drug development with innovative, therapeutic clinical trials that have as their scientific basis fundamental research performed in the Branch. Primary interests of the Branch concern the identification of abnormalities to the regulation of the immune response and the definition of molecular disorders that underlie lymphoid malignancies. The fundamental laboratory-based studies concern molecular biology of human lymphoid malignancies (Louis Staudt); the Staudt Laboratory uses genomic approaches to establish a molecular diagnosis of lymphoid malignancies and to discover new targets for therapy of these diseases.
A mainstay of the Laboratory is gene-expression profiling, which provides a foundation to understand the molecular pathogenesis of these cancers and their response to therapy. New molecular subtypes of lymphoma defined by gene-expression profiling emerge as distinct disease entities that differ in oncogenic mechanisms, as defined by other genomic technologies such as array-based comparative genomic hybridization and cancer gene resequencing. An ongoing interest is in RNA interference (RNAi)-based genetic screens for new therapeutic targets in lymphoma and multiple myeloma. A recurrent theme that emerges from these unbiased genetic approaches is that lymphoid malignancies co-opt signaling proteins and transcription factors that are used in normal B-cell differentiation and activation. These lymphoid restricted pathways provide opportunities for the development of targeted therapies for lymphoid cancers.
A major specific research goal of the Waldmann Laboratory immunological research program is to define the pivotal roles played by IL-2 and IL-15 (cytokine/cytokine receptors and signaling pathways) in the life and death of normal and neoplastic lymphocytes. Furthermore we clinically translate our basic discoveries of new cytokines (e.g., IL-15) and new cytokine receptors (e.g., IL-2R alpha and IL-2/IL-15R beta) and their signaling pathways through the use of IL-15 in immunotherapy and monoclonal antibodies to receptors (anti-IL-2R alpha and anti-IL-2/IL-15R beta) in the treatment of autoimmune diseases and lymphoid malignancies.
Our group also focuses on T-cell malignancies with special emphasis on human T-cell lymphotropic virus 1 (HTLV-1)-associated adult T-cell leukemia (ATL) (Kevin Conlon, Thomas Waldmann). A major goal of the Branch is to translate fundamental biologic insights into novel treatment of human B and T-cell lymphoid malignancies. The major clinical research emphasis is the development of the most effective therapeutic strategies in molecular subtypes of aggressive B-cell lymphomas. The dose-adjusted EPOCH-R platform has demonstrated excellent long-term results in Burkitt lymphoma as well as subsets of diffuse large B-cell lymphoma (DLBCL) such as primary mediastinal B-cell lymphoma (PMBL) and GCB DLBCL.
Collaboration with Louis Staudt, Wyndham Wilson and colleagues (Mark Roschewski) has led to the clinical development of novel agents that target pathways of ABC DLBCL such as the Bruton's tyrosine kinase inhibitor, ibrutinib. Currently, it is being prospectively tested in a multicenter study of DLBCL with MYC translocations.
Clinical Trials
-
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Open - Not yet RecruitingNCI Protocol ID NCI-21-C-0014Investigator Christopher J. Melani, M.D. -
A Phase 1 Study of Doxorubicin, CC-486 (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0169Investigator Milos Miljković, M.D., M.Sc. -
A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies#xD;
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0162Investigator Mark Roschewski, M.D. -
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/refractory T-cell Malignancies
Open - RecruitingNCI Protocol ID NCI-20-C-0127Investigator Milos Miljković, M.D., M.Sc. -
Avelumab (Bavencio) with IL-15 in subjects with clear-cell renal carcinoma
Open - RecruitingNCI Protocol ID NCI-20-C-0007Investigator Kevin C. Conlon, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell Lymphoma
Open - RecruitingNCI Protocol ID NCI-19-C-0116Investigator Mark Roschewski, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)
Open - RecruitingNCI Protocol ID NCI-19-C-0103Investigator Mark Roschewski, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Open - RecruitingNCI Protocol ID NCI-19-C-0076Investigator Milos Miljković, M.D., M.Sc.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Open - RecruitingNCI Protocol ID NCI-19-C-0024Investigator Milos Miljković, M.D., M.Sc.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
Open - RecruitingNCI Protocol ID NCI-17-C-0164Investigator Mark Roschewski, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
Phase 1b Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Open - RecruitingNCI Protocol ID NCI-17-C-0127Investigator Christopher J. Melani, M.D.Share this trial: Referral ContactsContact Name Phone Number -
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Open - RecruitingNCI Protocol ID NCI-17-C-0125Investigator Christopher J. Melani, M.D. -
Prospective Study of Clonal Evolution in Follicular Lymphoma
Open - RecruitingNCI Protocol ID NCI-17-C-0105Investigator Mark Roschewski, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 Sarah Evans 240.858.3541 -
Phase 1 Study of Ibrutinib and Immuno-chemotherapy using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Open - RecruitingNCI Protocol ID NCI-14-C-0157Investigator Mark Roschewski, M.D. -
Phase I/II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Smoldering and Chronic Adult T-cell Leukemia (ATL)
Open - RecruitingNCI Protocol ID NCI-13-C-0006Investigator Kevin C. Conlon, M.D.Share this trial: Referral ContactsContact Name Phone Number Medical Oncology Referral Office 301-451-1228 Medical Oncology Referral Office 866-611-6310 -
Collection of Blood, Bone Marrow and Tissue samples for the Investigation of the Human Immune Response, Lymphoma Biology and HTLV-1 Infection
Open - RecruitingNCI Protocol ID NCI-97-C-0143Investigator Thomas A. Waldmann, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050 -
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Open - RecruitingNCI Protocol ID NCI-94-C-0074Investigator Christopher J. Melani, M.D.Share this trial: Referral ContactsContact Name Phone Number NCI Medical Oncology Referral Office (240)760-6050
PI & Key Staff
Positions
There are no Open Positions at this time. Check back again later, or take a look at CCR's Careers page.
Contact Info
Center for Cancer Research
National Cancer Institute
Building 10, Room 4N115
Bethesda, MD 20892-1374
Ph: 240-858-3550
Fax: 240-541-4561